HighTide Therapeutics Completes Patient Enrolment for Phase II Trial of Metabolic Modulator
HighTide Therapeutics Completes Patient Enrolment for Phase II Trial of Metabolic Modulator
HighTide Therapeutics 完成代谢调节剂 II 期试验的患者入组
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册